scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1027852609 |
P356 | DOI | 10.1007/S11892-015-0640-3 |
P698 | PubMed publication ID | 26275442 |
P5875 | ResearchGate publication ID | 281055396 |
P2093 | author name string | Paul E Drawz | |
Scott Reule | |||
Boutros El-Haddad | |||
P2860 | cites work | Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease | Q79226809 |
Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion | Q81697684 | ||
Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms | Q24299673 | ||
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy | Q24657470 | ||
Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 | ||
Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats | Q28565932 | ||
Global estimates of the prevalence of diabetes for 2010 and 2030 | Q29547218 | ||
US Renal Data System 2012 Annual Data Report | Q30582337 | ||
Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats | Q31063566 | ||
Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 | ||
Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence | Q34321390 | ||
Sodium zirconium cyclosilicate in hyperkalemia | Q34448992 | ||
A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy | Q35025285 | ||
Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells | Q35032352 | ||
Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway | Q36598311 | ||
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 | ||
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study | Q37368689 | ||
Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions | Q38017616 | ||
Current concepts of renal hemodynamics in diabetes | Q40952838 | ||
Renal tubular hypertrophy induced by angiotensin II. | Q41605129 | ||
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. | Q42154496 | ||
Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats | Q43607543 | ||
Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus | Q44242766 | ||
Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats | Q44390510 | ||
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy | Q44390528 | ||
Plasma aldosterone concentration in the patient with diabetes mellitus | Q44845998 | ||
Effect of angiotensin II on glomerular structure in streptozotocin-induced diabetic rats | Q45148071 | ||
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats | Q45396552 | ||
Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 | ||
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension | Q46660460 | ||
Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells | Q46681426 | ||
Activation of a local renin angiotensin system in podocytes by glucose | Q46794009 | ||
Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats | Q47298474 | ||
Declining Incidence of Nephropathy in Insulin-Dependent Diabetes Mellitus | Q57449606 | ||
Improved prognosis of diabetic nephropathy in type 1 diabetes | Q61948356 | ||
Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? | Q67858660 | ||
Mortality of workers in two Minnesota taconite mining and milling operations | Q69832138 | ||
Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications | Q69890202 | ||
Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat | Q73293199 | ||
Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes | Q75205967 | ||
Angiotensin III up-regulates genes involved in kidney damage in mesangial cells and renal interstitial fibroblasts | Q77635349 | ||
P433 | issue | 10 | |
P304 | page(s) | 70 | |
P577 | publication date | 2015-10-01 | |
P1433 | published in | Current diabetes report | Q26841965 |
P1476 | title | Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise | |
P478 | volume | 15 |